

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/075,876	02/14/2002	Jean Fernand Armand Lacrampe	JAB 1694	9445
27777	7590 09/02/2004		EXAMINER	
PHILIP S. JOHNSON			BALASUBRAMANIAN, VENKATARAMAN	
JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA			ART UNIT	PAPER NUMBER
NEW BRUN	ISWICK, NJ 08933-7003	3	1624	
			DATE MAILED: 09/02/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Supplemental	10/075,876	LACRAMPE ET AL.				
Notice of Allowability	Examiner	Art Unit				
	Vl-taraman Balasukus siisi	1004				
	Venkataraman Balasubramanian	1624				
The MAILING DATE of this communication apperatus allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOT of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication IGHTS. This application is subject to	olication. If not included will be mailed in due course. THIS				
1. This communication is responsive to 6/14/2004.						
2. The allowed claim(s) is/are <u>1-11,14 and 15</u> .						
3. The drawings filed on are accepted by the Examine	r.					
 4. Acknowledgment is made of a claim for foreign priority unal (a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this national stage application from the						
International Bureau (PCT Rule 17.2(a)).		ational stage application from the				
* Certified copies not received:						
Applicant has THREE MONTHS FROM THE "MAILING DATE" on noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submit	ENT of this application.					
INFORMAL PATENT APPLICATION (PTO-152) which give	es reason(s) why the oath or declarati	ion is deficient.				
6. CORRECTED DRAWINGS (as "replacement sheets") mus						
(a) ☐ including changes required by the Notice of Draftspers	on's Patent Drawing Review (PTO-9	48) attached				
1) hereto or 2) to Paper No./Mail Date						
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	Amendment / Comment or in the Of	fice action of				
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the	84(c)) should be written on the drawing ne header according to 37 CFR 1.121(d)	gs in the front (not the back) of).				
7. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT F	sit of BIOLOGICAL MATERIAL m FOR THE DEPOSIT OF BIOLOGICA	ust be submitted. Note the L MATERIAL.				
Attachment(s)						
1. Notice of References Cited (PTO-892)	5. Notice of Informal Pa	tent Application (PTO-152)				
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary (I	•				
3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date 7/1/2004	Paper No /Mail Date					
4. ☐ Examiner's Comment Regarding Requirement for Deposit	8. 🔀 Examiner's Statemen	t of Reasons for Allowance				
of Biological Material	9. Other	The state of the s				

Art Unit: 1624

DETAILED ACTION

This is a supplemental action in response to applicants query regarding status of claims 12 and 13.

The amendment filed 26/04/2004 under 37 CFR 1.116 in reply to the final rejection has been considered and is made of record.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Gabriel Lopez on 05/13/2004.

1. Cancel claims 16-18.

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

In view of applicants' response, particularly pointing out that the priority date of instant application claims priority from EP9988701.0 filed 8/6/1999, and EP99126035.7, filed on 12/27/1999, and hence Freyne et al. is not a competent prior art, the prior art 102 and 103 rejections made in the previous office action have been deemed as obviated.

The compound of Formula I, namely 6-azauracil derivative, with specific X, R¹. R², R³, and R⁴ groups and along with specific p values, composition and method of treating eosinophil dependent inflammatory diseases embraced in the instant claims was not found to be anticipated or rendered obvious by the prior art of record. Additional search in the related art area also did not yield any prior art disclosing compound of formula I, with specific X, R1, R2, R3, R4 groups and p values, composition and method of treating eosinophil dependent inflammatory diseases embraced in the instant claims. Therefore, the examiner noted that the claims 1-11 and 14-15 would be in condition for allowance.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Application/Control Number: 10/075,876

Art Unit: 1624

Page 4

Any comments considered necessary by applicant must be submitted no later

than the payment of the issue fee and, to avoid processing delays, should preferably

accompany the issue fee. Such submissions should be clearly labeled "Comments on

Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication from the examiner should be

addressed to Venkataraman Balasubramanian (Bala) whose telephone number is (571)

272-0662. The examiner can normally be reached on Monday through Thursday from

8.00 AM to 6.00 PM. The Supervisory Patent Examiner (SPE) of the art unit 1624 is

Mukund Shah whose telephone number is (571) 272-0674. If Applicants are unable to

reach Mukund Shah within 24-hour period, they may contact James O. Wilson, Acting-

SPE of art unit 1624 at 571-272-0661.

The fax phone number for the organization where this application or proceeding

is assigned (703) 872-9306. Any inquiry of a general nature or relating to the status of

this application or proceeding should be directed to the receptionist whose telephone

number is (571) 272-1600.

V. Balasubramanian

8/26/2004